NMD逃逸机制及其在疾病治疗中的应用

无义介导的mRNA降解(nonsense-mediated mRNA decay, NMD)是指在病理或正常生理情况下mRNA上出现了提前终止密码子(premature termination codon, PTC),从而导致mRNA降解。它是一种广泛存在的mRNA质量监控机制。近年来,在多种疾病中发现某些PTC并未触发NMD,这种现象被称为NMD逃逸(NMD escape),然而其确切机制尚不十分清楚。目前公认的两个学说为:(1) PTC通读,即蛋白的翻译可以顺利通过PTC直至正常的终止密码子,产生全长蛋白;(2)翻译的重新启动,即蛋白翻译在PTC下游的潜在起始点重新开始直至终止密码子,产生N端截短蛋白。目前,通过利用PTC通读,越来越多的药物或小分子已被成功用于无义变异相关疾病的治疗。本文主要综述了NMD逃逸的机制及其在疾病治疗中的应用和进展,以期为进一步了解NMD逃逸及其相关应用概况提供参考。     

真核生物细胞中的无义介导mRNA降解机制

真核生物细胞具有不同的机制用于监视转录本的准确性以保证翻译产物的完整性与正确性．无义介导mRNA降解(NMD)的作用对象主要是由于编码氨基酸的密码子突变为终止密码子,而使翻译提前终止的无义mRNA,其降解方式是直接进行5′端脱帽和5′→3′方向的水解。     

PTC下游翻译的重新起始导致NMD途径的逃逸

无义突变介导的mRNA降解（nonsense mediated mRNA decay, NMD）途径是真核生物体内一种重要的mRNA监督质控机制, 它降解含有由无义突变、错误剪接、移码突变等产生的提前终止翻译密码子（premature translation termination codon, PTC）的mRNA, 从而防止这种mRNA翻译产生的截短型蛋白质对机体造成的伤害. 研究发现, 一些含有PTC的mRNA发生了NMD途径逃逸, 但具体机制仍不清楚.本研究将成视网膜细胞瘤基因1 (retinoblastoma gene 1, RB1)作为NMD途径的靶基因, 构建mini-RB1基因,包括外显子1～14(cDNA)、内含子14 外显子15 内含子15和外显子16～27(cDNA) 的三部分序列, 将其构建到真核表达载体pcDNA 3.1(-)中.根据人类基因组突变数据库选择3个突变位点W99X、G310X和R467X, 构建相应无义突变体.分别将mini RB1基因野生型和无义突变体转入HeLa细胞进行表达.用qRT-PCR检测发现, W99X无义突变体与野生型相比mRNA的水平无显著差异.为了进一步证实mini- RB1（W99X）发生了NMD逃逸, 利用NMD途径抑制剂放线菌酮和转录抑制剂放线菌素D, 分别处理转入野生型的mini RB1基因及其无义突变体mini-RB1（W99X）的哺乳动物细胞, 发现mini-RB1基因无义突变体的mRNA水平与野生型无明显差异, 说明含有W99X无义突变的mini-RB1基因的mRNA发生了NMD逃逸.Western印迹检测mini-RB1基因的蛋白质表达发现, 在无义突变位点W99X下游重新起始了蛋白质的翻译, 因此,PTC下游蛋白质翻译的重新起始可能是导致无义mRNA逃逸NMD途径监控的主要原因.     

无义介导的mRNA降解机制及其在单基因遗传病中的作用

无义介导的mRNA降解(Nonsense-mediated mRNA decay,NMD)是一种广泛存在于真核生物细胞中的mRNA质量监控机制。该机制通过识别和降解含有提前终止密码子(Premature translational-termination codon,PTC)的转录产物防止有潜在毒性的截短蛋白的产生。据估计,约1/3的遗传性疾病是由提前终止密码子引起的,而NMD作用通常会改变某些遗传病的临床症状或遗传方式。文章主要综述了人体细胞中NMD对底物的识别及其作用机制,并以几种单基因遗传病为例探讨其对这些疾病表型的影响,表明NMD作用机制的进一步揭示将有助于单基因遗传病发病机制的阐明及治疗方法的改进。     

PTC下游翻译重启导致NMD途径的逃逸

无义突变介导的mRNA降解(nonsense-mediated mRNA decay,NMD)途径是真核生物体内一种重要的mRNA监督质控机制,它降解含有由无义突变、错误剪接、移码突变等产生的提前终止翻译密码子(premature translation termination codon,PTC)的mRNA,从而防止这种mRNA翻译产生的截短型蛋白质对机体造成的伤害.研究发现,一些含有PTC的mRNA发生了NMD途径逃逸,但具体机制仍不清楚.本研究将成视网膜细胞瘤基因1(retinoblastoma gene 1,RB1)作为NMD途径的靶基因,构建mini-RB1基因,包括外显子1~14(c DNA)、内含子14-外显子15-内含子15和外显子16~27(c DNA)的三部分序列,将其构建到真核表达载体pc DNA 3.1(-)中.根据人类基因组突变数据库选择3个突变位点W99X、G310X和R467X,构建相应无义突变体.分别将mini-RB1基因野生型和无义突变体转入He La细胞进行表达.用qRT-PCR检测发现,W99X无义突变体与野生型相比mRNA的水平无显著差异.为了进一步证实mini-RB1(W99X)发生了NMD逃逸,利用NMD途径抑制剂放线菌酮和转录抑制剂放线菌素D,分别处理转入野生型的mini-RB1基因及其无义突变体mini-RB1(W99X)的哺乳动物细胞,发现mini-RB1基因无义突变体的mRNA水平与野生型无明显差异,说明含有W99X无义突变的mini-RB1基因的mRNA发生了NMD逃逸.Western印迹检测mini-RB1基因的蛋白质表达发现,在无义突变位点W99X下游重新起始了蛋白质的翻译,因此,PTC下游蛋白质翻译的重新起始可能是导致无义mRNA逃逸NMD途径监控的主要原因.     

蛋白质翻译过程中的忠实性机制

蛋白质合成的忠实性对细胞活力非常重要,否则会干扰细胞的生理过程,甚至导致疾病. 生物已经进化出多种机制以维持翻译的准确性,包括底物选择、校对和转肽后的质量控制机制.这些机制在氨基酸活化、翻译起始、延伸和终止等不同阶段发挥作用. 现在,对蛋白质合成的研究已经延伸到了其它领域,如病原体致病机制、耐药性,以及药物开发等. 本文主要综述了蛋白质合成起始、延伸和终止过程的忠实性机制,以及mRNA的质量控制方式,并对相关研究在抗生素药物及药物靶点开发方面的应用前景做了展望.     

真核生物无义介导的mRNA降解与肿瘤关系的研究进展

研究发现任何错误剪接、移码、插入等基因突变都可能引入含有提前终止密码子(premature termination codon,PTC)的转录产物,将导致翻译提前终止而产生无生物活性甚至毒害性截短蛋白(truncated proteins)。而无义介导的mRNA的降解(nonsensemediated m RNA decay,NMD)作用机制在基因转录及转录后加工过程中选择性地迅速降解含有提前终止密码子的mRNA,避免产生对细胞正常生理功能有害的截短蛋白,真核生物NMD是转录后m RNA监控的重要环节。肿瘤的发生发展与相应基因的表达有关,NMD可以降解含有PTC的mRNA,学者们认为抑制NMD后肿瘤中某些基因的表达上调,而上调的基因或许在肿瘤的发生发展中其抑癌基因的作用,故学者们抑制肿瘤中NMD后进行测序筛选发生无义突变的抑癌基因。     

一种新的Srrm1/SRm160可变剪接体经历无义突变介导的mRNA降解

目的:研究基因Srrm1/SRm160的可变剪接。方法:应用RT-PCR研究Srrm1/SRm160的可变剪接,通过蛋白质的翻译抑制和RNA干扰研究剪接异构体是否经历无义突变介导的mRNA降解(NMD)过程。结果:获得Srrm1/SRm160新的可变剪接异构体,该异构体产生提前终止密码子,翻译抑制和RNA干扰证实含有提前终止密码子的剪接体经过NMD而降解。结论:Srrm1/SRm160通过可变剪接和NMD调节自身的表达水平,作为剪接因子进一步调节其他基因的可变剪接。     

与剪接、翻译偶联的PRT—mRNA NMD降解机制

最新研究发现，真核细胞前体mRNA剪接不仅仅是前体mRNA的加工步骤，而且在翻译过程中也起到重要的监控作用，通过剪接，外显子－外显子连接点复合物结合于mRNA剪接位点上游20bp处，如果mRNA剪接位点上游大于50－55bp处出现无义突变，则这种翻译提前终止密码子mRNA将会在最后的翻译过程中通过外显子－外显子连接点复合物，Upf蛋白以及帽结合蛋白之间的相互作用，被引入脱帽，降解过程。     

亨廷顿舞蹈症发病机制的研究进展

亨廷顿舞蹈症是一种常染色体显性的神经退行性遗传病,由it-15基因外显子1发生CAG三核苷酸重复突变,引发其编码的亨廷顿蛋白多聚谷氨酰胺序列延长所致。突变亨廷顿蛋白导致大脑特定区域产生神经退行性病变的机制尚不明确。简要综述了亨廷顿舞蹈症发病机制的多种学说。     

Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice

The ability of aminoglycoside antibiotics to promote read-through of nonsense mutations has attracted interest in these drugs as potential therapeutic agents in genetic diseases. However, the toxicity of aminoglycoside antibiotics may result in severe side effects during long-term treatment. In this paper, we report that negamycin, a dipeptide antibiotic, also restores dystrophin expression in skeletal and cardiac muscles of the mdx mouse, an animal model of Duchenne muscular dystrophy (DMD) with a nonsense mutation in the dystrophin gene, and in cultured mdx myotubes. Dystrophin expression was confirmed by immunohistochemistry and immunoblotting. We also compared the toxicity of negamycin and gentamicin, and found negamycin to be less toxic. Furthermore, we demonstrate that negamycin binds to a partial sequence of the eukaryotic rRNA-decoding A-site. We conclude that negamycin is a promising new therapeutic candidate for DMD and other genetic diseases caused by nonsense mutations.     

Suppression of premature termination codons as a therapeutic approach

In this review, we describe our current understanding of translation termination and pharmacological agents that influence the accuracy of this process. A number of drugs have been identified that induce suppression of translation termination at in-frame premature termination codons (PTCs; also known as nonsense mutations) in mammalian cells. We discuss efforts to utilize these drugs to suppress disease-causing PTCs that result in the loss of protein expression and function. In-frame PTCs represent a genotypic subset of mutations that make up ~11% of all known mutations that cause genetic diseases, and millions of patients have diseases attributable to PTCs. Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases. Suppression therapy is currently in clinical trials for treatment of several genetic diseases caused by PTCs, and preliminary results suggest that some patients have shown clinical improvements. While current progress is promising, we discuss various approaches that may further enhance the efficiency of this novel therapeutic approach.     

Suppression of premature termination codons as a therapeutic approach

In this review, we describe our current understanding of translation termination and pharmacological agents that influence the accuracy of this process. A number of drugs have been identified that induce suppression of translation termination at in-frame premature termination codons (PTCs; also known as nonsense mutations) in mammalian cells. We discuss efforts to utilize these drugs to suppress disease-causing PTCs that result in the loss of protein expression and function. In-frame PTCs represent a genotypic subset of mutations that make up ~11% of all known mutations that cause genetic diseases, and millions of patients have diseases attributable to PTCs. Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases. Suppression therapy is currently in clinical trials for treatment of several genetic diseases caused by PTCs, and preliminary results suggest that some patients have shown clinical improvements. While current progress is promising, we discuss various approaches that may further enhance the efficiency of this novel therapeutic approach.     

Gene selective suppression of nonsense termination using antisense agents

An estimated one third of all inherited genetic disorders and many forms of cancer are caused by premature (nonsense) termination codons. Aminoglycoside antibiotics are candidate drugs for a large number of such genetic diseases; however, aminoglycosides are toxic, lack specificity and show low efficacy in this application. Because translational termination is an active process, we considered that steric hindrance by antisense sequences could trigger the ribosome's "default mode" of readthrough when positioned near nonsense codons. To test this hypothesis, we performed experiments using plasmids containing a luciferase reporter with amber, ochre and opal nonsense mutations within the luxB gene in Escherichia coli. The nonspecific termination inhibitors gentamicin and paromomycin and six antisense peptide nucleic acids (PNA) spanning the termination region were tested for their potential to suppress the luxB mutation. Gentamicin and paromomycin increased luciferase activity up to 2.5- and 10-fold, respectively. Two of the PNAs increased Lux activity up to 2.5-fold over control levels, with no significant effect on cell growth or mRNA levels. Thus, it is possible to significantly suppress nonsense mutations within target genes using antisense PNAs. The mechanism of suppression likely involves enhanced readthrough, but this requires further investigation. Nonsense termination in human cells may also be susceptible to suppression by antisense agents, providing a new approach to address numerous diseases caused by nonsense mutations.     

A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays

The drug molecule PTC124 (Ataluren) has been described as a read-through agent, capable of suppressing premature termination codons (PTCs) and restoring functional protein production from genes disrupted by nonsense mutations. Following the discovery of PTC124 there was some controversy regarding its mechanism of action with two reports attributing its activity to an off-target effect on the Firefly luciferase (FLuc) reporter used in the development of the molecule. Despite questions remaining as to its mechanism of action, development of PTC124 continued into the clinic and it is being actively pursued as a potential nonsense mutation therapy. To thoroughly test the ability of PTC124 to read through nonsense mutations, we conducted a detailed assessment comparing the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (G418) across a diverse range of in vitro reporter assays. We can confirm the off-target FLuc activity of PTC124 but found that, while G418 exhibits varying activity in every read-through assay, there is no evidence of activity for PTC124.     

Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through

Aminoglycoside-mediated read-through of stop codons was recently demonstrated for a variety of diseases in vitro and in vivo. About 30 percent of human genetic diseases are the consequence of nonsense mutations. Nonsense mutations in obesity-associated genes like the melanocortin 4 receptor (MC4R), expressed in the hypothalamus, show the impact of premature stop codons on energy homeostasis. Therefore, the MC4R could be a potential pharmaceutical target for obesity treatment and targeting MC4R stop mutations could serve as proof of principle for nonsense mutations in genes expressed in the brain. We investigated four naturally occurring nonsense mutations in the MC4R (W16X, Y35X, E61X, Q307X) located at different positions in the receptor for aminoglycoside-mediated functional rescue in vitro. We determined localization and amount of full-length protein before and after aminoglycoside treatment by fluorescence microscopy, cell surface and total enzyme linked immunosorbent assay (ELISA). Signal transduction properties were analyzed by cyclic adenosine monophosphate (cAMP) assays after transient transfection of MC4R wild type and mutant receptors into COS-7 cells. Functional rescue of stop mutations in the MC4R is dependent on: (i) triplet sequence of the stop codon, (ii) surrounding sequence, (iii) location within the receptor, (iv) applied aminoglycoside and ligand. Functional rescue was possible for W16X, Y35X (N-terminus), less successful for Q307X (C-terminus) and barely feasible for E61X (first transmembrane domain). Restoration of full-length proteins by PTC124 could not be confirmed. Future pharmaceutical applications must consider the potency of aminoglycosides to restore receptor function as well as the ability to pass the blood-brain barrier.     

Readthrough compounds for nonsense mutations: bridging the translational gap

Approximately 10% of all pathological mutations are nonsense mutations that are responsible for several severe genetic diseases for which no treatment regimens are currently available. The most widespread strategy for treating nonsense mutations is by enhancing ribosomal readthrough of premature termination codons (PTCs) to restore the production of the full-length protein. In the past decade several compounds with readthrough potential have been identified. However, although preclinical results on these compounds are promising, clinical studies have not yielded positive outcomes. We review preclinical and clinical research related to readthrough compounds and characterize factors that contribute to the observed translational gap.     

Rescue of nonsense mutations by amlexanox in human cells

ABSTRACT: BACKGROUND: Nonsense mutations are at the origin of many cancers and inherited genetic diseases. The consequence of nonsense mutations is often the absence of mutant gene expression due to the activation of an mRNA surveillance mechanism called nonsense-mediated mRNA decay (NMD). Strategies to rescue the expression of nonsense-containing mRNAs have been developed such as NMD inhibition or nonsense mutation readthrough. METHODS: Using a dedicated screening system, we sought molecules capable to block NMD. Additionally, 3 cell lines derived from patient cells and harboring a nonsense mutation were used to study the effect of the selected molecule on the level of nonsense-containing mRNAs and the synthesis of proteins from these mutant mRNAs. RESULTS: We demonstrate here that amlexanox, a drug used for decades, not only induces an increase in nonsense-containing mRNAs amount in treated cells, but also leads to the synthesis of the full-length protein in an efficient manner. We also demonstrated that these full length proteins are functional. CONCLUSIONS: As a result of this dual activity, amlexanox may be useful as a therapeutic approach for diseases caused by nonsense mutations.